As an example, the oncogene c-Myc is a known inhibitor of TXNIP in multiple cancers, TXNIPlow/Mychigh induces metabolic reprogramming and is a marker of poor prognosis in breast cancer [53], and therapy resistance [54, 55]. Here, TXNIP is linked to breast carcinoma.